{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:44:47Z","timestamp":1707525887868},"reference-count":28,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2,8]]},"DOI":"10.7759\/cureus.53849","type":"journal-article","created":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T15:56:10Z","timestamp":1707407770000},"source":"Crossref","is-referenced-by-count":0,"title":["Study of Lipid-Modifying Therapy Use and Risk Factor Management in Patients With Dyslipidemia in Duhok City\/Kurdistan Region, Iraq"],"prefix":"10.7759","author":[{"given":"Sipan","family":"Sarbast","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamal B","family":"Mohamad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1177\/1747493019832996","article-title":"Anthology of stroke epidemiology in the 20th and 21st centuries: assessing the past, the present, and envisioning the future","volume":"14","author":"Feigin VL","year":"2019","unstructured":"Feigin VL. Anthology of stroke epidemiology in the 20th and 21st centuries: assessing the past, the present, and envisioning the future. Int J Stroke. 2019, 14:223-237. 10.1177\/1747493019832996","journal-title":"Int J Stroke"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000485","article-title":"Heart Disease and Stroke Statistics-2017 update: a report from the American Heart Association","volume":"135","author":"Benjamin EJ","year":"2017","unstructured":"Benjamin EJ, Blaha MJ, Chiuve SE, et al.. Heart Disease and Stroke Statistics-2017 update: a report from the American Heart Association. Circulation. 2017, 135:146-603. 10.1161\/CIR.0000000000000485","journal-title":"Circulation"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2011.02.001","article-title":"Total cardiovascular risk approach to improve efficiency of cardiovascular prevention in resource constrain settings","volume":"64","author":"Mendis S","year":"2011","unstructured":"Mendis S, Lindholm LH, Anderson SG, et al.. Total cardiovascular risk approach to improve efficiency of cardiovascular prevention in resource constrain settings. J Clin Epidemiol. 2011, 64:1451-1462. 10.1016\/j.jclinepi.2011.02.001","journal-title":"J Clin Epidemiol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1177\/1010539510373034","article-title":"Cardiovascular disease in the Asia Middle East region: global trends and local implications","volume":"22","author":"Ramahi TM","year":"2010","unstructured":"Ramahi TM. Cardiovascular disease in the Asia Middle East region: global trends and local implications. Asia Pac J Public Health. 2010, 22:83S-89S. 10.1177\/1010539510373034","journal-title":"Asia Pac J Public Health"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsha.2014.09.004","article-title":"Primary prevention with statins in cardiovascular diseases: a Saudi Arabian perspective","volume":"27","author":"Mahmood D","year":"2015","unstructured":"Mahmood D, Jahan K, Habibullah K. Primary prevention with statins in cardiovascular diseases: a Saudi Arabian perspective. J Saudi Heart Assoc. 2015, 27:179-191. 10.1016\/j.jsha.2014.09.004","journal-title":"J Saudi Heart Assoc"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2174\/1874944502114010264","article-title":"Ten-year mortality trends and natural causes of death in the Iraqi Kurdistan","volume":"14","author":"Salih SO","year":"2021","unstructured":"Salih SO, Moramarco S, Di Giovanni D, Qadir SA, Alsilefanee HH, Basa FB, Gialloreti LE. Ten-year mortality trends and natural causes of death in the Iraqi Kurdistan. Open Public Health J. 2021, 14:264-271. 10.2174\/1874944502114010264","journal-title":"Open Public Health J"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1186\/s12944-021-01450-8","article-title":"Prevalence of plasma lipid disorders with an emphasis on LDL cholesterol in selected countries in the Asia-Pacific region","volume":"20","author":"Lee ZV","year":"2021","unstructured":"Lee ZV, Llanes EJ, Sukmawan R, Thongtang N, Ho HQ, Barter P. Prevalence of plasma lipid disorders with an emphasis on LDL cholesterol in selected countries in the Asia-Pacific region. Lipids Health Dis. 2021, 20:33. 10.1186\/s12944-021-01450-8","journal-title":"Lipids Health Dis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61368-4","article-title":"Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials","volume":"385","author":"Fulcher J","year":"2015","unstructured":"Fulcher J, O'Connell R, Voysey M, et al.. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015, 385:1397-1405. 10.1016\/S0140-6736(14)61368-4","journal-title":"Lancet"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1177\/2047487317708677","article-title":"Early, intensive statin treatment reduces 'hard' cardiovascular outcomes after acute coronary syndrome","volume":"24","author":"Schwartz GG","year":"2017","unstructured":"Schwartz GG, Fayyad R, Szarek M, DeMicco D, Olsson AG. Early, intensive statin treatment reduces 'hard' cardiovascular outcomes after acute coronary syndrome. Eur J Prev Cardiol. 2017, 24:1294-1296. 10.1177\/2047487317708677","journal-title":"Eur J Prev Cardiol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa JC","year":"2005","unstructured":"LaRosa JC, Grundy SM, Waters DD, et al.. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005, 352:1425-1435. 10.1056\/NEJMoa050461","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000133317.49796.0E","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines","volume":"110","author":"Grundy SM","year":"2004","unstructured":"Grundy SM, Cleeman JI, Merz CN, et al.. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004, 110:227-239. 10.1161\/01.CIR.0000133317.49796.0E","journal-title":"Circulation"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9149(00)01464-8","article-title":"High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High--Density Lipoprotein Intervention Trial","volume":"86","author":"Boden WE","year":"2000","unstructured":"Boden WE. High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High--Density Lipoprotein Intervention Trial. Am J Cardiol. 2000, 86:19-22. 10.1016\/s0002-9149(00)01464-8","journal-title":"Am J Cardiol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000013593","article-title":"Comparison of efficacy and safety of combination therapy with statins and omega-3 fatty acids versus statin monotherapy in patients with dyslipidemia: a systematic review and meta-analysis","volume":"97","author":"Choi HD","year":"2018","unstructured":"Choi HD, Chae SM. Comparison of efficacy and safety of combination therapy with statins and omega-3 fatty acids versus statin monotherapy in patients with dyslipidemia: a systematic review and meta-analysis. Medicine (Baltimore). 2018, 97:e13593. 10.1097\/MD.0000000000013593","journal-title":"Medicine (Baltimore)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.173114","article-title":"Statins and PCSK9 inhibitors: a new lipid-lowering therapy","volume":"878","author":"Gallego-Colon E","year":"2020","unstructured":"Gallego-Colon E, Daum A, Yosefy C. Statins and PCSK9 inhibitors: a new lipid-lowering therapy. Eur J Pharmacol. 2020, 878:173114. 10.1016\/j.ejphar.2020.173114","journal-title":"Eur J Pharmacol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"37","author":"Catapano AL","year":"2016","unstructured":"Catapano AL, Graham I, De Backer G, et al.. 2016 ESC\/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2016, 37:2999-3058. 10.1093\/eurheartj\/ehw272","journal-title":"Eur Heart J"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)","volume":"41","author":"Mach F","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, et al.. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2020, 41:111-188. 10.1093\/eurheartj\/ehz455","journal-title":"Eur Heart J"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s10354-013-0219-z","article-title":"Are there differences in LDL-C target value attainment in Austrian federal states? Yes!","volume":"163","author":"Pichler M","year":"2013","unstructured":"Pichler M, Lautsch D, Adler C, et al.. Are there differences in LDL-C target value attainment in Austrian federal states? Yes!. Wien Med Wochenschr. 2013, 163:528-535. 10.1007\/s10354-013-0219-z","journal-title":"Wien Med Wochenschr"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1093\/ehjqcco\/qcaa023","article-title":"Statin dose titration patterns and subsequent major cardiovascular events in very high-risk patients: estimates from Swedish population-based registry data","volume":"6","author":"Banefelt J","year":"2020","unstructured":"Banefelt J, Lindh M, Svensson MK, Eliasson B, Tai MH. Statin dose titration patterns and subsequent major cardiovascular events in very high-risk patients: estimates from Swedish population-based registry data. Eur Heart J Qual Care Clin Outcomes. 2020, 6:323-331. 10.1093\/ehjqcco\/qcaa023","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.12997\/jla.2019.8.2.242","article-title":"Dyslipidemia and rate of under-target low-density lipoprotein-cholesterol in patients with coronary artery disease in Korea","volume":"8","author":"Lee SH","year":"2019","unstructured":"Lee SH, Song WH, Jeong MH, et al.. Dyslipidemia and rate of under-target low-density lipoprotein-cholesterol in patients with coronary artery disease in Korea. J Lipid Atheroscler. 2019, 8:242-251. 10.12997\/jla.2019.8.2.242","journal-title":"J Lipid Atheroscler"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2018-314253","article-title":"Sub-optimal cholesterol response to initiation of statins and future risk of cardiovascular disease","volume":"105","author":"Akyea RK","year":"2019","unstructured":"Akyea RK, Kai J, Qureshi N, Iyen B, Weng SF. Sub-optimal cholesterol response to initiation of statins and future risk of cardiovascular disease. Heart. 2019, 105:975-981. 10.1136\/heartjnl-2018-314253","journal-title":"Heart"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwaa047","article-title":"EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study","volume":"28","author":"Ray KK","year":"2021","unstructured":"Ray KK, Molemans B, Schoonen WM, et al.. EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study. Eur J Prev Cardiol. 2021, 28:1279-1289. 10.1093\/eurjpc\/zwaa047","journal-title":"Eur J Prev Cardiol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s00508-021-01978-w","article-title":"Lipid lowering therapy in primary and secondary prevention in Austria: are LDL-C goals achieved?: Results from the DA\u00a0VINCI study","volume":"134","author":"Siostrzonek P","year":"2022","unstructured":"Siostrzonek P, Brath H, Zweiker R, Drexel H, Hoelzl R, Hemetsberger M, Ray KK. Lipid lowering therapy in primary and secondary prevention in Austria: are LDL-C goals achieved?: Results from the DA\u00a0VINCI study. Wien Klin Wochenschr. 2022, 134:294-301. 10.1007\/s00508-021-01978-w","journal-title":"Wien Klin Wochenschr"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.4103\/HEARTVIEWS.HEARTVIEWS_32_18","article-title":"Prevalence of lipid abnormalities and cholesterol target value attainment in patients with stable and acute coronary heart disease in the United Arab Emirates","volume":"20","author":"Al Mahmeed W","year":"2019","unstructured":"Al Mahmeed W, Bakir S, Beshyah SA, et al.. Prevalence of lipid abnormalities and cholesterol target value attainment in patients with stable and acute coronary heart disease in the United Arab Emirates. Heart Views. 2019, 20:37-46. 10.4103\/HEARTVIEWS.HEARTVIEWS_32_18","journal-title":"Heart Views"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0084350","article-title":"Results of the Dyslipidemia International Study (DYSIS)-Middle East: clinical perspective on the prevalence and characteristics of lipid abnormalities in the setting of chronic statin treatment","volume":"9","author":"Al Sifri SN","year":"2014","unstructured":"Al Sifri SN, Almahmeed W, Azar S, et al.. Results of the Dyslipidemia International Study (DYSIS)-Middle East: clinical perspective on the prevalence and characteristics of lipid abnormalities in the setting of chronic statin treatment. PLoS One. 2014, 9:e84350. 10.1371\/journal.pone.0084350","journal-title":"PLoS One"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.25675","article-title":"Statins and LDL-C in secondary prevention-So much progress, so far to go","volume":"3","author":"Banach M","year":"2020","unstructured":"Banach M, Penson PE. Statins and LDL-C in secondary prevention-So much progress, so far to go. JAMA Netw Open. 2020, 3:e2025675. 10.1001\/jamanetworkopen.2020.25675","journal-title":"JAMA Netw Open"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2021.01.009","article-title":"Lipid-lowering therapies: better together","volume":"320","author":"Banach M","year":"2021","unstructured":"Banach M, Penson PE. Lipid-lowering therapies: better together. Atherosclerosis. 2021, 320:86-88. 10.1016\/j.atherosclerosis.2021.01.009","journal-title":"Atherosclerosis"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-019-7827-5","article-title":"Prevalence and risk factors for dyslipidemia among adults in rural and urban China: findings from the China National Stroke Screening and prevention project (CNSSPP)","volume":"19","author":"Opoku S","year":"2019","unstructured":"Opoku S, Gan Y, Fu W, et al.. Prevalence and risk factors for dyslipidemia among adults in rural and urban China: findings from the China National Stroke Screening and prevention project (CNSSPP). BMC Public Health. 2019, 19:1500. 10.1186\/s12889-019-7827-5","journal-title":"BMC Public Health"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.12816\/0045301","article-title":"Risk factors of dyslipidemia among Saudi population 2017","volume":"71","author":"Alzahrani GS","year":"2018","unstructured":"Alzahrani GS, Aljehani SM, Al-Johani JJ. Risk factors of dyslipidemia among Saudi population 2017. Egypt J Hosp Medicine. 2018, 71:2262-2265. 10.12816\/0045301","journal-title":"Egypt J Hosp Medicine"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/223278-study-of-lipid-modifying-therapy-use-and-risk-factor-management-in-patients-with-dyslipidemia-in-duhok-citykurdistan-region-iraq","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:18:38Z","timestamp":1707506318000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/223278-study-of-lipid-modifying-therapy-use-and-risk-factor-management-in-patients-with-dyslipidemia-in-duhok-citykurdistan-region-iraq"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,8]]},"references-count":28,"URL":"https:\/\/doi.org\/10.7759\/cureus.53849","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,8]]}}}